Methicillin-Resistant Staphyloccocus Aureus Infections (MRSA) | Current Treatment | Physician Insights | US | 2017

The relatively recent FDA approvals of tedizolid (Merck’s Sivextro), dalbavancin (Allergan’s Dalvance), and oritavancin (The Medicines Company’s Orbactiv) for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) highlight the competitive nature of the hospital-treated MRSA market. Further, with the recent generic availability of the key anti-MRSA agents linezolid (Pfizer’s Zyvox) and daptomycin (Merck’s Cubicin), new and older brands will need to offer improvements in key areas of differentiation to gain uptake in this crowded market. This report analyzes the current and anticipated MRSA inpatient treatment landscape, providing critical information for manufacturers to position their products based on differentiating attributes that differentiate them from the competition to maximize uptake in the high-value hospital market segment.

QUESTIONS ANSWERED

•  What percentage of patients received empiric treatment covering MRSA in eight common indications, including ABSSSI and osteomyelitis? What is the success rate of empiric treatment for these MRSA patients?
• What are the most prescribed first-, second-, and third-line anti-MRSA therapies for inpatients with ABSSSI, bloodstream infection, nosocomial pneumonia, orand community-acquired bacterial pneumonia? What are the patients shares for key anti-MRSA agents in these indications?
• What are the percentages of MRSA patients thatwho are ineligible for different key anti-MRSA agents? What are the common reasons that MRSA patients are ineligible for linezolid and daptomycin?
•  What are the physician-reported drivers and constraints determining current prescribing patterns and recent/anticipated changes?